Leuprorelin-Induced Thrombocytopenia Successfully Treated With Surgical Resection of the Injection Site.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
a subcutaneous injection of long-acting (24-week) leuprorelin depot as androgen deprivation therapy for prostate cancer
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
After the surgery, his platelet count drastically recovered and platelet transfusion became unnecessary. [CONCLUSION] We report a case of leuprorelin-induced thrombocytopenia that was successfully treated with surgical resection of the injection site.
[INTRODUCTION] Drug-induced thrombocytopenia (DITP) can be caused by many kinds of drugs.
APA
Mori R, Taguchi S, et al. (2025). Leuprorelin-Induced Thrombocytopenia Successfully Treated With Surgical Resection of the Injection Site.. IJU case reports, 8(4), 365-368. https://doi.org/10.1002/iju5.70041
MLA
Mori R, et al.. "Leuprorelin-Induced Thrombocytopenia Successfully Treated With Surgical Resection of the Injection Site.." IJU case reports, vol. 8, no. 4, 2025, pp. 365-368.
PMID
40607457 ↗
Abstract 한글 요약
[INTRODUCTION] Drug-induced thrombocytopenia (DITP) can be caused by many kinds of drugs. Its treatment generally involves discontinuation of the responsible drug.
[CASE PRESENTATION] A 70-year-old man received a subcutaneous injection of long-acting (24-week) leuprorelin depot as androgen deprivation therapy for prostate cancer. Four days after the injection, he presented with gingival bleeding and his platelet count was remarkably decreased (< 1000/μL). There was no sign of malignancy but the presence of megakaryocytes on bone-marrow examinations. Considering immune and/or DITP, he started immunoglobulin and steroid therapy while stopping all suspected medications. However, even a month later, his platelet count did not recover with the need for frequent platelet transfusions. Therefore, he eventually underwent surgical resection of the leuprorelin injection site. After the surgery, his platelet count drastically recovered and platelet transfusion became unnecessary.
[CONCLUSION] We report a case of leuprorelin-induced thrombocytopenia that was successfully treated with surgical resection of the injection site.
[CASE PRESENTATION] A 70-year-old man received a subcutaneous injection of long-acting (24-week) leuprorelin depot as androgen deprivation therapy for prostate cancer. Four days after the injection, he presented with gingival bleeding and his platelet count was remarkably decreased (< 1000/μL). There was no sign of malignancy but the presence of megakaryocytes on bone-marrow examinations. Considering immune and/or DITP, he started immunoglobulin and steroid therapy while stopping all suspected medications. However, even a month later, his platelet count did not recover with the need for frequent platelet transfusions. Therefore, he eventually underwent surgical resection of the leuprorelin injection site. After the surgery, his platelet count drastically recovered and platelet transfusion became unnecessary.
[CONCLUSION] We report a case of leuprorelin-induced thrombocytopenia that was successfully treated with surgical resection of the injection site.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration-Sensitive Prostate Cancer.
- Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer.
- PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.
- GSTA1 deficiency drives neuroendocrine differentiation via TNFRSF13B/c-FOS/CHGA axis in prostate cancer.